What is Keytruda and what is it used for?

Keytruda, as one of the leading representatives of modern immunotherapy, is an innovative treatment that aims to reactivate the body’s own immune system against cancer cells. Unlike traditional chemotherapies, instead of directly attacking cells, it blocks the PD-1 pathway, which suppresses the immune response, enabling the defense mechanisms to recognize and destroy tumors. Therefore, it stands out for offering promising results in many different tumor types, such as lung cancer, melanoma, bladder cancer, and lymphoma.

What is Keytruda?

Keytruda is an immunotherapy drug in the PD-1 inhibitor (immune checkpoint blocker) class that contains the active ingredient pembrolizumab and enables the immune system to recognize and target cancer cells. Cancer cells use a suppressive pathway called PD-1 to prevent immune cells from recognizing them; Keytruda blocks this immune signal, allowing the immune system to reactivate and develop a strong defense against tumors. This treatment, which can be used in many different tumor types, including melanoma, lung cancer, bladder cancer, head and neck cancers, and certain hematological malignancies, has become an important component of personalized treatment strategies, particularly among targeted immunotherapies.

Keytruda Description and Drug Classification

Keytruda’s active ingredient, pembrolizumab, is a monoclonal antibody belonging to the class of immune checkpoint inhibitors. This class of drugs works by targeting the PD-1 (Programmed Death-1) receptor located on the surface of immune cells. Normally, the PD-1 pathway acts as a “brake mechanism” to keep the immune response in balance, but cancer cells abuse this mechanism to hide from the immune system. By blocking PD-1, Keytruda disables this brake, allowing immune cells, particularly T lymphocytes, to recognize and destroy tumor cells again. Therefore, unlike conventional chemotherapies, which directly target the tumor, it is positioned in the class of immunotherapy that restores the immune system’s capacity to fight cancer.

Its Place Among Immunotherapy Treatments

It is one of the most effective and widely used agents in the checkpoint inhibitor category. In modern oncology, immunotherapy is an umbrella treatment approach aimed at reactivating the body’s defense mechanisms against the tumor; within this approach, PD-1/PD-L1 blockade is one of the most important milestones. By targeting PD-1, it deactivates this checkpoint and allows T cells to emerge from their suppressed state in the tumor microenvironment. This feature makes it one of the immunotherapy options that can achieve long-term responses in both cases that have developed resistance to chemotherapy and in advanced-stage cancers such as metastatic disease. Furthermore, with its superior response rates in patients with biomarkers such as high tumor mutation burden (TMB-H), microsatellite instability (MSI-H), or PD-L1 positivity, it reinforces the critical role of immunotherapy in personalized treatment strategies.

Which Patients Is It Recommended For?

It is preferred in patients whose immune system’s capacity to target cancer cells can be measured via biological markers and who have a high potential for response to immunotherapy. Especially in tumors with high PD-L1 expression, it shows effective response rates, making the PD-L1 score a critical determinant in treatment decisions for many cancer types. In addition, patients carrying genomic alterations such as MSI-H (high microsatellite instability) or TMB-H (high tumor mutation burden) are among the groups that benefit most from Keytruda, as it allows the immune system to mount a stronger response against the tumor.

In clinical practice, it can be used in a wide variety of cancer types, including metastatic melanoma, advanced non-small cell lung cancer, urothelial cancer, head and neck cancers, lymphoma, and some gastrointestinal tumors. It also constitutes an important option for switching to immunotherapy in patients who have developed resistance to chemotherapy or who have not responded to other systemic treatments.

What is Keytruda Used For?

To understand its clinical effect, it’s necessary to consider both the drug’s role on the immune system and why it has found widespread use in different tumor types. This immunotherapy not only reactivates T cells but also breaks down the suppressive structure of the tumor microenvironment, potentially eliciting significant responses in a wide variety of cancer types. The rapid expansion of FDA approvals over the years is a result of the scientific evidence proving its potential to deliver sustainable and profound responses, even in tumors with diverse biological structures.

How Does Keytruda Support the Immune System’s Fight Against Cancer?

It helps T cells, which are suppressed in the tumor microenvironment, regain their functional capacity. Normally, tumor cells create an “immune defense zone” by releasing cytokines and suppressor cells (such as Treg and MDSC) that weaken the immune response. Keytruda’s ability to deactivate the PD-1 pathway allows T cells in this suppressive microenvironment to return to their essential defense functions, such as proliferation, cytotoxic activity, and interferon-gamma production. This enables the immune system not only to recognize the tumor but also to overcome the tumor’s immunosuppressive barrier.

FDA Approved Uses

Approved by the FDA for numerous indications that have been expanded over time, it is one of the agents with the broadest range of uses among immunotherapies. Approved uses include:

• Metastatic or adjuvant melanoma
• Non-small cell lung cancer (NSCLC) – both alone and in combination, depending on PD-L1
• Small cell lung cancer (SCLC)
• Head and neck squamous cell carcinoma
• Urothelial (bladder) cancer
• Gastric and gastroesophageal junction cancers
• Hodgkin lymphoma and primary mediastinal B-cell lymphoma
• Cervical cancer – in PD-L1 positive cases
• Microsatellite instability (MSI-H) or TMB-H tumors – one of the first FDA approvals regardless of tumor type
• Liver cancer (HCC)
• Kidney cancer (RCC) – in combination protocols

This broad list of indications reflects the drug’s mechanism of action, which can be effective in different tumor biobiomes, and the robust responses it has demonstrated in global data.

Which Cancer Types Is It Effective Against?

The cancer types it is effective against are generally tumors with strong escape mechanisms based on suppression of the immune system. Among the cancer types where the best responses are obtained are:

Melanoma: One of the tumors that initiated the immunotherapy era due to the reporting of long-term complete responses even in advanced stages.

Lung Cancer (NSCLC and SCLC): Provides significant advantages in terms of both survival and treatment tolerance in patients with high PD-L1 positivity.

Bladder Cancer: An effective second-line option in cases where resistance develops after conventional chemotherapy.

Head and Neck Cancers: Can offer better response times than chemotherapy, especially in recurrent or metastatic cases.

MSI-H and TMB-H Tumors: Keytruda is significantly successful in this group because of its high genetic instability, which creates more neoantigens that can be recognized by the immune system.

Lymphomas: Response rates are quite high, especially in Hodgkin lymphoma, due to PD-L1 gene amplification.

In addition to this list, its use is increasingly expanding in combination therapy protocols (for example, in combination with chemotherapy, targeted therapies, or other immunotherapies) in different tumors.

How does Keytruda work?

Its mechanism of action is based on reactivating the recognition and attack functions of the immune system that are suppressed by cancer cells. The drug blocks the PD-1 receptor on T cells, disabling the tumor’s immune brake and thus enabling defense cells to mount a more effective, sustainable, and targeted response against the tumor.

How Does PD-1/PD-L1 Blockade Work?

The PD-1 pathway acts as a natural “brake mechanism” to keep the immune system’s overreactions under control. Cancer cells, however, abuse this mechanism by overproducing a protein called PD-L1 on their surface, which binds to the PD-1 receptor on T cells, rendering them inactive. Directly targeting PD-1 prevents this interaction. This eliminates the immune suppression caused by cancer, allowing T cells to reactivate in the tumor area and receive the necessary signals to initiate an immune response. This blockade is one of the most important molecular steps forming the basis of immunotherapy.

Activation of Immune Cells

When PD-1 signaling is deactivated, T cells, previously suppressed in the tumor microenvironment, return to their essential functions such as proliferation, cytotoxic granule release, and cytokine production. In particular, the activation of CD8+ cytotoxic T cells is the most powerful step in fighting cancer. Thanks to their regained activity, these cells penetrate deeper into the tumor tissue and gain the capacity to simultaneously attack numerous tumor cells.

The Process of Recognizing and Destroying Cancer Cells

Once activated, T cells first recognize neoantigens on the surface of tumor cells. These antigens are unique markers created by cancer through mutations and allow the immune system to distinguish the tumor from other healthy cells. Once recognition occurs, T cells release cytotoxic molecules such as perforin and granzyme, disrupting the cell membrane and initiating programmed cell death (apoptosis). In addition, signals like interferon-gamma trigger a broader immune response around the tumor. This process is not limited to destroying individual cells; over time, it can lead to a reduction in tumor mass and, in some patients, long-term disease control.

What is Keytruda Used For?

It is a broad-spectrum immunotherapy option used to enable the immune system to control cancer in various tumor types. It is preferred in advanced, metastatic disease or disease resistant to standard treatments to slow tumor growth, stabilize the disease, or in some cases achieve significant tumor regression.

Lung Cancer

This is one of the primary immunotherapies used as a first-line treatment or in combination with chemotherapy, particularly in patients with non-small cell lung cancer (NSCLC), depending on PD-L1 expression levels. Its ability to provide a survival advantage even when used alone in patients with high PD-L1 levels has made it a standard component of NSCLC treatment. Effective results have also been obtained in second-line treatment for patients who show disease progression after chemotherapy. In small cell lung cancer (SCLC), it may be preferred to slow the aggressive course of the disease in recurrent cases.

Melanoma (Skin Cancer)

Melanoma is one of the tumor types that responds best to immunotherapy, and Keytruda is used as a significant treatment option in this area in adjuvant, neoadjuvant, and metastatic stages. Its ability to reduce the risk of recurrence after surgery, observe long-term complete responses in metastatic disease, and effectively target melanoma cells with a high mutation burden, gives the drug a strong position in this tumor group. It can also be integrated into combination strategies with targeted therapies in cases with BRAF mutations.

Kidney, Bladder, Head and Neck, Cervical, and Other Cancers

Its broad range of indications stems from its immunological mechanism, which can be effective in different tumor biomass.

Kidney cancer (RCC): It is usually used in combination with other immunotherapies or targeted agents.

Bladder cancer: It is an important option in cases where the disease has progressed after chemotherapy or where there is no response to treatments administered into the bladder.

Head and neck cancers: It can provide more sustainable responses compared to chemotherapy, especially in metastatic or recurrent cases.

Cervical cancer: It is an approved immunotherapy option in PD-L1 positive tumors and can significantly slow the rate of disease progression.

In addition, it has applications in stomach, esophageal, liver, and some types of lymphoma, supported by clinical data.

Role in Metastatic and Advanced Stage Disease Treatments

Its most significant effect is seen in metastatic or advanced-stage disease that has developed resistance to treatment. In these stages, the immune system is usually suppressed by the tumor microenvironment; Keytruda removes this suppression, allowing T cells to become active again. As a result, it is possible to slow the tumor growth rate, keep the disease stable, or achieve long-term responses in some patients. Its ability to provide longer-term control compared to conventional treatments has made the drug a critical tool in advanced-stage oncology protocols.

How Much Does Keytruda Extend Life Expectancy?

While it doesn’t yield the same results in every patient, clinical studies have shown that, especially in patients with the correct biomarkers, it can not only slow the disease but also provide a survival advantage lasting for years in some cases.

Impact on Survival According to Clinical Trials

Its impact on survival has been evaluated in large-scale clinical trials conducted on different tumor types, and these results are one of the most significant areas where immunotherapy differs from classical chemotherapy. This is a form not seen in classical treatments in statistical curves: while the bottom of the curve approaches the base over time, a certain percentage of patients receiving Keytruda remain above the line for an extended period.

Diseases where this effect is most pronounced include:

PD-L1 ≥ 50% NSCLC: Reported to nearly double median survival compared to chemotherapy.

Melanoma: In some studies, 5-year survival rates have reached a high threshold considered the beginning of the immunotherapy era.

MSI-H / TMB-H tumors: Shown to significantly increase long-term stable disease rates, even in patients resistant to chemotherapy.

In Which Stages Is It Most Effective?

Its strongest clinical effect is generally seen in metastatic or locally advanced disease; because in these stages, the tumor burden is high, the suppression on the immune system is also significant, and the benefit obtained from PD-1 blockade becomes clearer. However, its ability to reduce the risk of recurrence in some cancer types when used as an adjuvant after surgery has shown that the drug is not limited only to advanced stage treatment. Particularly in melanoma and lung cancer, clinical data support its ability to reduce the likelihood of disease recurrence in high-risk early-stage patients.

Patient-Specific Factors

The effect on survival does not manifest in the same way in every patient because the treatment response is directly dependent on the biological characteristics of the tumor and the patient’s immune capacity. The most important determinants include PD-L1 levels, genetic profiles such as MSI-H/TMB-H, degree of tumor spread, comorbidities, age, performance status, and previous treatments received by the patient. For example, a long-term response may be achieved in a patient with a strong immune reserve and high PD-L1 positivity; however, the response may be more limited in a patient under intense tumor pressure and with poor general health. Therefore, treatment planning always requires individual assessment, and the potential impact of Keytruda can only be accurately predicted by considering patient-specific clinical variables.

How Much Does Keytruda Cost?

It varies greatly depending on the country, health insurance coverage, the number of doses administered, and the number of treatment sessions. The cost of a single dose is quite high in many countries, and the total treatment cost is calculated individually for each patient. A personalized cost plan is created taking into account the patient’s dosage schedule, treatment duration, and local health policies.

Does the State Cover Keytruda?

This depends on the country’s reimbursement policies, the diagnosis of the disease, biomarker criteria such as PD-L1, and the patient’s treatment stage. While some countries offer partial or full reimbursement for specific cancer types and patient profiles, in other cases, patient co-payments may be required. Therefore, reimbursement status must be evaluated specifically for each country and patient case.

In Turkey, reimbursement status depends on the current Health Application Communiqué (SUT) criteria of the Social Security Institution (SGK) and is not automatically covered for every patient. Generally:

• Certain cancer types,
• Certain treatment stages,
• If biomarker conditions such as PD-L1 level are met,

It may be covered by SGK reimbursement. However, this coverage is not valid for all patients or all tumor types and is subject to frequently updated legislation.

Keytruda Use and Treatment Process

It is administered as regular infusions at dose intervals determined according to the patient’s clinical condition and the biological characteristics of the tumor. The treatment process consists of stages such as evaluating the response, monitoring possible side effects, and following the course of the disease with imaging methods at specific intervals.

Method of Administration (Intravenous Infusion)

Administered as an intravenous infusion via a vein. Each session typically lasts around 30 minutes, and patients need to come to the hospital or chemotherapy unit for treatment. The patient’s vital signs are monitored during administration because initial doses in immunotherapy can trigger early immune reactions in some patients. Since the drug does not replicate spontaneously in the body or carry a targeted molecule, its effect continues via the immune system after the infusion is complete.

Treatment Frequency and Follow-up Process

Treatment is generally administered at intervals of 3 or 6 weeks; the chosen interval depends on the patient’s clinical characteristics and dosage schedule. Throughout treatment, the patient’s response is monitored using regular imaging methods (such as CT, MRI, PET-CT). The first follow-up is usually done after 2–3 months because temporary pseudoprogression of the tumor in the early stages is not uncommon in immunotherapies. The decision to continue treatment is made based on the tumor’s response, the patient’s tolerance, and the manageability of any side effects.

Side Effects and Management

Unlike conventional chemotherapies, side effects manifest as immune-mediated toxicities resulting from excessive or faulty activation of the immune system. The most common side effects include fatigue, skin rashes, thyroid dysfunction, diarrhea, or colitis. Less common but serious reactions include pneumonia, elevated liver enzymes (hepatitis), or endocrine disorders affecting hormone balance. When these side effects occur, treatment is often temporarily stopped and controlled with immunosuppressive drugs such as corticosteroids. Regular blood tests, hormone level monitoring, and clinical evaluations form the basis of side effect management.

Who Cannot Use Keytruda?

It is not a suitable treatment for everyone; its use may be limited in some patients, particularly those at risk of immune system overstimulation. It should be carefully considered in individuals with serious autoimmune diseases, active infections, or those using immunosuppressive therapy.

Patients with Autoimmune Diseases

The use of Keytruda should be carefully considered in individuals with autoimmune diseases (e.g., lupus, rheumatoid arthritis, Crohn’s disease, multiple sclerosis). Because the drug reactivates the immune system, it may further trigger an already overactive or misguided immune response. This could lead to a worsening of existing autoimmune disease or the development of new immune-mediated complications. Therefore, treatment decisions in these patients should be made considering the level of control of the autoimmune disease and a risk-benefit assessment.

Organ Transplant Patients

Immunotherapies carry serious risks in organ transplant patients because they can increase the risk of rejection of the transplanted organ by eliminating the suppressed immune system. This risk is particularly high after kidney or liver transplants. Therefore, they should only be considered in exceptional cases and under very close monitoring in organ transplant recipients; they are not preferred in most clinical situations.

Use During Pregnancy and Breastfeeding

Its use during pregnancy is not recommended because its effects on the fetus are not fully known. The drug is an antibody that can cross the placenta and may affect fetal immunity development. During breastfeeding, it is not clearly known whether the drug passes into breast milk; therefore, it is recommended to discontinue breastfeeding during treatment. Patients planning to become pregnant should definitely discuss this with their doctor before starting treatment.

Let’s Plan Your Right Treatment Journey Together.

Advanced immunotherapy options like Keytruda require careful patient selection, detailed file analysis, and professional treatment coordination. At QBA Medi Tours, we meticulously manage the entire process for you, from evaluating your medical reports and determining appropriate treatment options to contacting expert centers and providing step-by-step information throughout the process. Our goal is to provide a reliable, transparent, and scientifically based treatment journey, enabling you to make the right decisions at the right time.

Blood test results and immune system findings must be interpreted correctly during cancer treatment. In particular, low white blood cell count doesn’t always mean cancer. You can find more detailed information on this topic in our blog post, Is Low White Blood Count Cancerous? 

For comprehensive information on surgical, chemotherapy, and immunotherapy options used in cancer treatment, please visit our Cancer Treatment page.

If you would like to receive a personal assessment of Keytruda treatment or alternative immunotherapy options, you can contact us and request detailed information from our expert consultants.

Frequently Asked Questions

How long does it take for Keytruda treatment to start showing results?

Its effectiveness is usually assessed in the first imaging checks performed within 6–12 weeks. However, since it is possible for the tumor to appear to grow initially (pseudoprogression) in immunotherapies, the true response may take longer to become clear in some patients.

Can Keytruda be used in combination with chemotherapy?

Yes. In some types of cancer, particularly lung cancer, combination with chemotherapy can provide higher response rates. The suitability of the combination is determined by the tumor type, stage, and the patient’s overall health.

What happens if Keytruda overstimulates the immune system?

Overstimulation of the immune system can lead to immune-mediated side effects. Conditions such as thyroid disorders, colitis, skin rashes, and lung inflammation (pneumonitis) may develop. These reactions can usually be controlled with immunomodulatory therapies such as corticosteroids.

Does Keytruda treatment yield the same results in every patient?

No. Treatment response varies depending on factors such as PD-L1 level, tumor mutation burden, MSI status, disease extent, and the patient’s immune capacity. Therefore, the same degree of benefit is not expected in every patient.

How is the duration of Keytruda treatment determined?

The duration of treatment is generally determined by the tumor’s response, the manageability of side effects, and the patient’s clinical condition. Many protocols plan a maximum treatment duration of 2 years; however, this duration may vary depending on the individual patient.

Which medications should be avoided during Keytruda treatment?

Immunosuppressant drugs (high-dose corticosteroids, some biological agents) may reduce its effectiveness. Certain treatments used for active infections also require caution. It is important for the patient to inform their doctor of all medications.

Is complete remission possible with Keytruda?

Yes, long-term complete responses (deep remission) have been reported, particularly in melanoma and some types of lung cancer. However, this outcome is not seen in everyone and depends on the patient’s biological characteristics.

What are the most common side effects of Keytruda?

The most common side effects are fatigue, loss of appetite, skin rashes, diarrhea, thyroid hormone disorders, and joint pain. Less common but serious side effects include pneumonitis, hepatitis, and other immune-mediated organ inflammations.

Source

ibas, A. (2015). Releasing the brakes on cancer immunotherapy: PD-1 and PD-L1 blockade. Cancer Research, 75(11), 2139–2145.

Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., … & Brahmer, J. R. (2015).
Overall survival and long-term safety of nivolumab (anti–PD-1) in patients with previously treated advanced non–small-cell lung cancer.
Journal of Clinical Oncology, 33(18), 2004–2012.
https://doi.org/10.1200/JCO.2014.58.3708

Sharpe, A. H., & Pauken, K. E. (2018).
The diverse functions of the PD-1 inhibitory pathway in cancer.
Nature Reviews Immunology, 18(3), 153–167.
https://doi.org/10.1038/nri.2017.108